{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:41:02Z","timestamp":1784234462787,"version":"3.55.0"},"reference-count":24,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,5,1]]},"abstract":"<jats:p>Objectives. Treatment with pamidronate improves the clinical course in children with osteogenesis imperfecta (OI), but theoretically might affect longitudinal growth. In this study we analyzed growth during cyclical intravenous pamidronate treatment in children and adolescents (age .04\u201315.6 years at baseline) with moderate to severe forms of OI types I, III, and IV.<\/jats:p>\n               <jats:p>Methods. The effect of 1 year of pamidronate treatment on height and weight was analyzed in 116 patients (OI-I, N = 29; OI-III, N = 42; OI-IV, N = 45). The results of 4 years of therapy were evaluated in 41 children (OI-I, N = 12; OI-III, N = 14; OI-IV, N = 15).<\/jats:p>\n               <jats:p>Results. Baseline height was low for age in all OI types. After 1 year of pamidronate therapy, height z scores had increased significantly in OI-III (by 0.3 \u00b1 0.8, mean \u00b1 standard deviation; P = .04) and did not change in OI-I and OI-IV. Weight z scores increased significantly in OI-I (by 0.2 \u00b1 0.4, P = .01). After 4 years of pamidronate therapy, mean height z scores increased significantly in OI-IV (by 0.41 \u00b1 0.71, P = .04), whereas nonsignificant trends to increase were found for OI-I and OI-III. When height was expressed as a percentage of the result expected for untreated patients with the same OI type, long-term pamidronate therapy was associated with a significant height gain in all 3 OI types (P &amp;lt; .001). Eight patients who reached final height after 3.0 \u00b1 1.0 years of treatment were taller on average than expected for untreated patients (P = .04).<\/jats:p>\n               <jats:p>Conclusions. Four years of cyclical intravenous pamidronate treatment led to a significant height gain in moderately to severely affected OI patients.<\/jats:p>","DOI":"10.1542\/peds.111.5.1030","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:43:47Z","timestamp":1092444227000},"page":"1030-1036","source":"Crossref","is-referenced-by-count":149,"title":["Height and Weight Development During Four Years of Therapy With Cyclical Intravenous Pamidronate in Children and Adolescents With Osteogenesis Imperfecta Types I, III, and IV"],"prefix":"10.1542","volume":"111","author":[{"given":"Leonid","family":"Zeitlin","sequence":"first","affiliation":[{"name":"From the Genetics Unit, Shriners Hospital for Children and McGill University, Montre\u0301al, Que\u0301bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rauch","sequence":"additional","affiliation":[{"name":"From the Genetics Unit, Shriners Hospital for Children and McGill University, Montre\u0301al, Que\u0301bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"Plotkin","sequence":"additional","affiliation":[{"name":"From the Genetics Unit, Shriners Hospital for Children and McGill University, Montre\u0301al, Que\u0301bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis H.","family":"Glorieux","sequence":"additional","affiliation":[{"name":"From the Genetics Unit, Shriners Hospital for Children and McGill University, Montre\u0301al, Que\u0301bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2003,5,1]]},"reference":[{"key":"2021121003373547600_R1","doi-asserted-by":"crossref","unstructured":"Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet.1979;16:101\u2013116","DOI":"10.1136\/jmg.16.2.101"},{"key":"2021121003373547600_R2","doi-asserted-by":"crossref","unstructured":"Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine.1997;76:266\u2013283","DOI":"10.1097\/00005792-199707000-00005"},{"key":"2021121003373547600_R3","doi-asserted-by":"crossref","unstructured":"Bembi B, Parma A, Bottega M, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr.1997;131:622\u2013625","DOI":"10.1016\/S0022-3476(97)70074-X"},{"key":"2021121003373547600_R4","doi-asserted-by":"crossref","unstructured":"Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med.1998;339:947\u2013952","DOI":"10.1056\/NEJM199810013391402"},{"key":"2021121003373547600_R5","doi-asserted-by":"crossref","unstructured":"Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab.2000;85:1846\u20131850","DOI":"10.1210\/jcem.85.5.6584"},{"key":"2021121003373547600_R6","doi-asserted-by":"crossref","unstructured":"Lee YS, Low SL, Lim LA, Loke KY. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr.2001;160:641\u2013644","DOI":"10.1007\/s004310100844"},{"key":"2021121003373547600_R7","doi-asserted-by":"crossref","unstructured":"Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child.2002;86:356\u2013364","DOI":"10.1136\/adc.86.5.356"},{"key":"2021121003373547600_R8","doi-asserted-by":"crossref","unstructured":"Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev.1998;19:80\u2013100","DOI":"10.1210\/edrv.19.1.0325"},{"key":"2021121003373547600_R9","doi-asserted-by":"crossref","unstructured":"Srivastava T, Alon US. Bisphosphonates: from grandparents to grandchildren. Clin Pediatr.1999;38:687\u2013702","DOI":"10.1177\/000992289903801201"},{"key":"2021121003373547600_R10","unstructured":"Baron RE. Anatomy and ultrastructure of bone. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 1999:3\u201310"},{"key":"2021121003373547600_R11","doi-asserted-by":"crossref","unstructured":"Miller SC, Jee WS, Woodbury DM, Kemp JW. Effects of N,N,N\u2032,N\u2032-ethylenediaminetetramethylene phosphonic acid and 1-hydroxyethylidene-1,1-bisphosphonic acid on calcium absorption, plasma calcium, longitudinal bone growth, and bone histology in the growing rat. Toxicol Appl Pharmacol.1985;77:230\u2013239","DOI":"10.1016\/0041-008X(85)90322-9"},{"key":"2021121003373547600_R12","doi-asserted-by":"crossref","unstructured":"Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int.1986;38:342\u2013349","DOI":"10.1007\/BF02555748"},{"key":"2021121003373547600_R13","doi-asserted-by":"crossref","unstructured":"Pataki A, Muller K, Green JR, Ma YF, Li QN, Jee WS. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat Rec.1997;249:458\u2013468","DOI":"10.1002\/(SICI)1097-0185(199712)249:4<458::AID-AR5>3.0.CO;2-N"},{"key":"2021121003373547600_R14","doi-asserted-by":"crossref","unstructured":"Lepola VT, Hannuniemi R, Kippo K, Lauren L, Jalovaara P, Vaananen HK. Long-term effects of clodronate on growing rat bone. Bone.1996;18:191\u2013196","DOI":"10.1016\/8756-3282(95)00439-4"},{"key":"2021121003373547600_R15","doi-asserted-by":"crossref","unstructured":"Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, van de Kamp JJ, Papapoulos SE. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr.1997;156:792\u2013794","DOI":"10.1007\/s004310050715"},{"key":"2021121003373547600_R16","doi-asserted-by":"crossref","unstructured":"Glorieux FH, Rauch F, Plotkin H, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res.2000;15:1650\u20131658","DOI":"10.1359\/jbmr.2000.15.9.1650"},{"key":"2021121003373547600_R17","doi-asserted-by":"crossref","unstructured":"Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res.2002;17:30\u201338","DOI":"10.1359\/jbmr.2002.17.1.30"},{"key":"2021121003373547600_R18","doi-asserted-by":"crossref","unstructured":"Ward LM, Rauch F, Travers R, et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone.2002;31:12\u201318","DOI":"10.1016\/S8756-3282(02)00790-1"},{"key":"2021121003373547600_R19","doi-asserted-by":"crossref","unstructured":"Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist. 2nd ed. Stanford, CA: Stanford University Press; 1959","DOI":"10.1097\/00000441-195909000-00030"},{"key":"2021121003373547600_R20","doi-asserted-by":"crossref","unstructured":"Hamill PV, Drizd TA, Johnson CL, Reed RB, Roche AF, Moore WM. Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr.1979;32:607\u2013629","DOI":"10.1093\/ajcn\/32.3.607"},{"key":"2021121003373547600_R21","doi-asserted-by":"crossref","unstructured":"Luhmann SJ, Sheridan JJ, Capelli AM, Schoenecker PL. Management of lower-extremity deformities in osteogenesis imperfecta with extensible intramedullary rod technique: a 20-year experience. J Pediatr Orthop.1998;18:88\u201394","DOI":"10.1097\/01241398-199801000-00017"},{"key":"2021121003373547600_R22","doi-asserted-by":"crossref","unstructured":"Vetter U, Pontz B, Zauner E, Brenner RE, Spranger J. Osteogenesis imperfecta: a clinical study of the first ten years of life. Calcif Tissue Int.1992;50:36\u201341","DOI":"10.1007\/BF00297295"},{"key":"2021121003373547600_R23","doi-asserted-by":"crossref","unstructured":"Rowe DW, Shapiro JR. Osteogenesis imperfecta. In: Avioli LV, Krane SM, eds. Metabolic Bone Disease and Clinically Related Disorders. 3rd ed. San Diego, CA: Academic Press; 1998:651\u2013695","DOI":"10.1016\/B978-012068700-8\/50024-4"},{"key":"2021121003373547600_R24","doi-asserted-by":"crossref","unstructured":"Cropp GJ, Myers DN. Physiological evidence of hypermetabolism in osteogenesis imperfecta. Pediatrics.1972;49:375\u2013391","DOI":"10.1542\/peds.49.3.375"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/111\/5\/1030\/1002219\/pe0503001030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/111\/5\/1030\/1002219\/pe0503001030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T10:32:32Z","timestamp":1639132352000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/111\/5\/1030\/63343\/Height-and-Weight-Development-During-Four-Years-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,1]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2003,5,1]]},"published-print":{"date-parts":[[2003,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.111.5.1030","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,1]]}}}